Effects of TNP-470, a potent angiogenesis inhibitor, on growth of hematopoietic progenitors.
Hasuike
T
T
Hino
M
M
Yamane
T
T
Nishizawa
Y
Y
Morii
H
H
Tatsumi
N
N
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011239:Prednisolone / Q000008:administration & dosage; D012717:Sesquiterpenes / Q000494:pharmacology*; D014750:Vincristine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D000077609:O-(Chloroacetylcarbamoyl)fumagillol